M3db

Metastatic melanoma patients have a poor prognosis attributable to the underlying heterogeneity in the melanoma driver genes and altered gene expression profiles which also makes development of drugs and identification of novel drug targets for metastatic melanoma a daunting task. Systems biology offers an alternative approach to re-explore the genes or gene sets that display dysregulated behaviour without being differentially expressed. In this study, we have performed systems biology studies to enhance our knowledge about the conserved property of disease genes or gene sets among mutually exclusive datasets representing melanoma progression.